Matenda a autoimmune, omwe ali amitundu yosiyanasiyana ndipo nthawi zambiri amakhala osagwirizana komanso oopsa, ndi amodzi mwamagawo ofunikira pakukula kwa mankhwala.JAK-STAT ndi imodzi mwama immunomodulatory pathways omwe atsimikiziridwa, makamaka JAK inhibitors.Mankhwala ambiri,monga tofacitinib, zakhala zikugulitsidwa padziko lonse lapansi.

Cholinga cha JAK chapangidwa kwa zaka zosakwana 20, koma pakadali pano mitundu pafupifupi 7 yavomerezedwa kuti igulidwe.Zizindikiro zake makamaka ndi zotupa ndi matenda odziteteza okha, ndipo zowongoleredwanso ndizomwe zimawonekera makamaka m'mafupa fibrosis ndi nyamakazi ya nyamakazi.Zotsatirazi zikuyang'ana pa JAK inhibitor yoyamba (tofacitinib) yochizira nyamakazi ya nyamakazi.

Tofacitinib ndi molekyu yaying'ono yapakamwa ya JAK inhibitor yopangidwa ndi Pfizer.Ili ndi kusankha kwabwino kwa JAK.Mu Novembala 2012, US FDA idavomereza tofacitinib citrate pochiza methotrexate kuyankha kosakwanira kapena kosagwirizana ndi chithandizo.Chida ichi ndi choletsa choyamba cha JAK chovomerezedwa ndi FDA pochiza nyamakazi ya nyamakazi.Pakalipano, kuwonjezera pa zizindikiro zovomerezeka, tofacitinib ikuyesedwanso kuti igwire ntchito mu ankylosing spondylitis, atopic dermatitis, keratoconjunctivitis sicca ndi Crohn's disease.Pankhani yogulitsa padziko lonse lapansi, kugulitsa kwapachaka kwa tofacitinib mu 2017 kunali kopitilira US $ 1 biliyoni, ndipo kugulitsa kwapachaka mu 2019 kwafika US $ 2.242 biliyoni.

Njira zosiyanasiyana zopangidwira zidzakhudza kwambiri zokolola ndi mtundu wa ma API.Kuphatikizika kwathu kwa tofacitinib citrate kumapewa njira yovomerezeka.Njira yopangira imafuna ndalama zotsika mtengo, zokolola zambiri, zonyansa zamtundu umodzi ndi chiyero zimatha kuyendetsedwa mosiyanasiyana, kapena zitha kusinthidwa ndi makasitomala.Chifukwa chake titha kukhala ndi mwayi wowonekera pamsika.Pakalipano mphamvu yathu ikhoza kukhala 50kg pamwezi, ndipo tofacitinib citrate imatumizidwa kale ku USA, Mexico, Franch, Bangladesh, ndi zina.